Dermatological Disorders in Parkinson's Disease
The first suggestion of an increased risk of melanoma in Parkinson disease (PD) patients was reported by Skibba et al. (Arch Pathol 93:556-561, 1972) in 1972. They reported a 55-year-old male with PD who developed a local recurrence of a primary melanoma and multiple primary melanomas 4 years after primary excision and 4 months after starting levodopa. Since levodopa is a metabolite in the biosynthesis of dopamine and melanin involving the enzyme tyrosinase, and increased tyrosinase activity is found in melanoma, they speculated that levodopa "could enhance and stimulate growth on any residual melanoma tissue". © Springer Science+Business Media New York 2013.
Milestones in Drug Therapy
Skinner, R., & LeDoux, M. (2013). Dermatological Disorders in Parkinson's Disease. Milestones in Drug Therapy, 24, 237-242. https://doi.org/10.1007/978-1-60761-429-6_16